Levamisole as adjuvant immunotherapy in breast cancer
- 1 May 1987
- Vol. 59 (9) , 1590-1593
- https://doi.org/10.1002/1097-0142(19870501)59:9<1590::aid-cncr2820590911>3.0.co;2-r
Abstract
Results are reported of a double‐blind randomized study on 198 patients with resectable node positive mammary cancer, evaluating the effect of the immune modulating drug levamisole in an adjuvant setting. Drug treatment was started after completion of postoperative radiotherapy. In a two‐arm trial 97 patients used levamisole and 101 patients used a placebo. No difference was noted in overall survival and disase‐free survival between the two groups. Toxicity was reason for discontinuation of the drug in 30 of 97 of the patients in the levamisole group and 8/101 in the placebo group.This publication has 4 references indexed in Scilit:
- Levamisole in the treatment of stage II breast cancerfive-year follow-up of a randomized double-blind studyCancer, 1985
- Adjuvant radiotherapy trials in breast cancerCancer, 1977
- LEVAMISOLE IN ADVANCED HUMAN BREAST CANCERThe Lancet, 1976
- Regression Models and Life-TablesJournal of the Royal Statistical Society Series B: Statistical Methodology, 1972